CK2 regulates 5-HT4 receptor signaling and modulates depressive-like behavior

Abstract

The serotonergic neurotransmitter system has been widely implicated in the pathophysiology of mood-related disorders such as anxiety and major depressive disorder (MDD). The onset of therapeutic efficacy of traditional antidepressants is delayed by several weeks. The 5-HT4 receptor has emerged as a new therapeutic target since agonists of this receptor induce rapid antidepressant-like responses in rodents. Here we show that the 5-HT4 receptor is regulated by CK2, at transcriptional and post-transcriptional levels. We present evidence, in two different CK2α knockout mouse lines, that this regulation is region-specific, with the 5-HT4 receptor upregulated in prefrontal cortex (PFC) but not striatum or hippocampus where CK2α is also ablated. 5-HT4 receptor signaling is enhanced in vitro, as evidenced by enhanced cAMP production or receptor plasma membrane localization in the presence of CK2 inhibitor or shRNA targeting CK2α. In vivo, 5-HT4 receptor signaling is also upregulated since ERK activation is elevated and sensitive to the inverse agonist, GR113808 in the PFC of CK2α KO mice. Behaviorally, KO mice as well as mice with AAV-mediated deletion of CK2α in the PFC show a robust ‘anti-depressed-like’ phenotype and display an enhanced response to antidepressant treatment when tested in paradigms for mood and anxiety. Importantly, it is sufficient to overexpress the 5-HT4 receptor in the mPFC to generate mice with a similar ‘anti-depressed-like’ phenotype. Our findings identify the mPFC as the region that mediates the effect of enhanced 5-HT4 receptor activity and CK2 as modulator of 5-HT4 receptor levels in this brain region that regulates mood-related phenotypes.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

References

  1. 1

    Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE . Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593–602.

  2. 2

    Lee JC, Blumberger DM, Fitzgerald P, Daskalakis Z, Levinson A . The role of transcranial magnetic stimulation in treatment-resistant depression: a review. Curr Pharm Des 2012; 18: 5846–5852.

  3. 3

    Mendez-David I, David DJ, Darcet F, Wu MV, Kerdine-Romer S, Gardier AM et al. Rapid anxiolytic effects of a 5-HT(4) receptor agonist are mediated by a neurogenesis-independent mechanism. Neuropsychopharmacology 2014; 39: 1366–1378.

  4. 4

    Samuels BA, Mendez-David I, Faye C, David SA, Pierz KA, Gardier AM et al. Serotonin 1A and Serotonin 4 receptors: essential mediators of the neurogenic and behavioral actions of antidepressants. Neuroscientist 2016; 22: 26–45.

  5. 5

    Pascual-Brazo J, Castro E, Diaz A, Valdizan EM, Pilar-Cuellar F, Vidal R et al. Modulation of neuroplasticity pathways and antidepressant-like behavioural responses following the short-term (3 and 7 days) administration of the 5-HT(4) receptor agonist RS67333. Int J Neuropsychopharmacol 2012; 15: 631–643.

  6. 6

    Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S et al. Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron 2007; 55: 712–725.

  7. 7

    Gomez-Lazaro E, Garmendia L, Beitia G, Perez-Tejada J, Azpiroz A, Arregi A . Effects of a putative antidepressant with a rapid onset of action in defeated mice with different coping strategies. Prog Neuropsychopharmacol Biol Psychiatry 2012; 38: 317–327.

  8. 8

    Barbon A, Caracciolo L, Orlandi C, Musazzi L, Mallei A, La Via L et al.Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. Neurochem Int 2011; 59: 896–905.

  9. 9

    Tamburella A, Micale V, Navarria A, Drago F . Antidepressant properties of the 5-HT4 receptor partial agonist, SL65.0155: behavioral and neurochemical studies in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1205–1210.

  10. 10

    Schmidt EF, Warner-Schmidt JL, Otopalik BG, Pickett SB, Greengard P, Heintz N . Identification of the cortical neurons that mediate antidepressant responses. Cell 2012; 149: 1152–1163.

  11. 11

    Madsen K, Torstensen E, Holst KK, Haahr ME, Knorr U, Frokjaer VG et al. Familial risk for major depression is associated with lower striatal 5-HT(4) receptor binding. Int J Neuropsychopharmacol 2014; 18: 1–7.

  12. 12

    Ohtsuki T, Ishiguro H, Detera-Wadleigh SD, Toyota T, Shimizu H, Yamada K et al. Association between serotonin 4 receptor gene polymorphisms and bipolar disorder in Japanese case-control samples and the NIMH Genetics Initiative Bipolar Pedigrees. Mol Psychiatry 2002; 7: 954–961.

  13. 13

    Trembley JH, Chen Z, Unger G, Slaton J, Kren BT, Van Waes C et al. Emergence of protein kinase CK2 as a key target in cancer therapy. BioFactors 2010; 36: 187–195.

  14. 14

    Filhol O, Cochet C . Protein kinase CK2 in health and disease: cellular functions of protein kinase CK2: a dynamic affair. Cell Mol Life Sci 2009; 66: 1830–1839.

  15. 15

    Diaz-Nido J, Mizuno K, Nawa H, Marshak DR . Regulation of protein kinase CK2 isoform expression during rat brain development. Cell Mol Biol Res 1994; 40: 581–585.

  16. 16

    Bischoff N, Olsen B, Raaf J, Bretner M, Issinger OG, Niefind K . Structure of the human protein kinase CK2 catalytic subunit CK2alpha' and interaction thermodynamics with the regulatory subunit CK2beta. J Mol Biol 2011; 407: 1–12.

  17. 17

    Chung HJ, Huang YH, Lau LF, Huganir RL . Regulation of the NMDA receptor complex and trafficking by activity-dependent phosphorylation of the NR2B subunit PDZ ligand. J Neurosci 2004; 24: 10248–10259.

  18. 18

    Sanz-Clemente A, Matta JA, Isaac JT, Roche KW . Casein kinase 2 regulates the NR2 subunit composition of synaptic NMDA receptors. Neuron 67: 984–996.

  19. 19

    Lee G, Tanaka M, Park K, Lee SS, Kim YM, Junn E et al. Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation. J Biol Chem 2004; 279: 6834–6839.

  20. 20

    Watanabe T, Huang HB, Horiuchi A, da Cruze Silva EF, Hsieh-Wilson L, Allen PB et al. Protein phosphatase 1 regulation by inhibitors and targeting subunits. Proc Natl Acad Sci USA 2001; 98: 3080–3085.

  21. 21

    Gao Z, Lee P, Stafford JM, von Schimmelmann M, Schaefer A, Reinberg D . An AUTS2-polycomb complex activates gene expression in the CNS. Nature 2014; 516: 349–354.

  22. 22

    Rebholz H, Zhou M, Nairn AC, Greengard P, Flajolet M . Selective knockout of the casein kinase 2 in d1 medium spiny neurons controls dopaminergic function. Biol Psychiatry 2013; 74: 113–121.

  23. 23

    Gardier AM, Guiard BP, Guilloux JP, Reperant C, Coudore F, David DJ . Interest of using genetically manipulated mice as models of depression to evaluate antidepressant drugs activity: a review. Fundam Clin Pharmacol 2009; 23: 23–42.

  24. 24

    Li X, Morrow D, Witkin JM . Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying. Life Sci 2006; 78: 1933–1939.

  25. 25

    Gorski JA, Talley T, Qiu M, Puelles L, Rubenstein JL, Jones KR . Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage. J Neurosci 2002; 22: 6309–6314.

  26. 26

    Maroteaux L, Saudou F, Amlaiky N, Boschert U, Plassat JL, Hen R . Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers. Proc Natl Acad Sci USA 1992; 89: 3020–3024.

  27. 27

    Ruf BM, Bhagwagar Z . The 5-HT1B receptor: a novel target for the pathophysiology of depression. Curr Drug Targets 2009; 10: 1118–1138.

  28. 28

    Lanfumey L, Hamon M . 5-HT1 receptors. Curr Drug Targets CNS Neurol Disord 2004; 3: 1–10.

  29. 29

    McDevitt RA, Hiroi R, Mackenzie SM, Robin NC, Cohn A, Kim JJ et al. Serotonin 1B autoreceptors originating in the caudal dorsal raphe nucleus reduce expression of fear and depression-like behavior. Biol Psychiatry 2011; 69: 780–787.

  30. 30

    Bonaventure P, Hall H, Gommeren W, Cras P, Langlois X, Jurzak M et al. Mapping of serotonin 5-HT(4) receptor mRNA and ligand binding sites in the post-mortem human brain. Synapse 2000; 36: 35–46.

  31. 31

    Bockaert J, Claeysen S, Compan V, Dumuis A . 5-HT4 receptors. Curr Drug Targets CNS Neurol Disord 2004; 3: 39–51.

  32. 32

    Savitz J, Drevets WC . Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev 2009; 33: 699–771.

  33. 33

    Mayberg HS . Targeted electrode-based modulation of neural circuits for depression. J Clin Invest 2009; 119: 717–725.

  34. 34

    Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999; 45: 1085–1098.

  35. 35

    Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 2006; 311: 77–80.

  36. 36

    Egeland M, Warner-Schmidt J, Greengard P, Svenningsson P . Co-expression of serotonin 5-HT(1B) and 5-HT(4) receptors in p11 containing cells in cerebral cortex, hippocampus, caudate-putamen and cerebellum. Neuropharmacology 2011; 61: 442–450.

  37. 37

    Heiman M, Schaefer A, Gong S, Peterson JD, Day M, Ramsey KE et al. A translational profiling approach for the molecular characterization of CNS cell types. Cell 2008; 135: 738–748.

  38. 38

    Fanselow MS, Dong HW . Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 2010; 65: 7–19.

  39. 39

    Hallegger M, Sobala A, Smith CW . Four exons of the serotonin receptor 4 gene are associated with multiple distant branch points. RNA 2010; 16: 839–851.

  40. 40

    Rebholz H, Nishi A, Liebscher S, Nairn AC, Flajolet M, Greengard P . CK2 negatively regulates Galphas signaling. Proc Natl Acad Sci USA 2009; 106: 14096–14101.

  41. 41

    Norum JH, Hart K, Levy FO, Ras-dependent ERK . activation by the human G(s)-coupled serotonin receptors 5-HT4(b) and 5-HT7(a). J Biol Chem 2003; 278: 3098–3104.

  42. 42

    Barthet G, Framery B, Gaven F, Pellissier L, Reiter E, Claeysen S et al. 5-hydroxytryptamine 4 receptor activation of the extracellular signal-regulated kinase pathway depends on Src activation but not on G protein or beta-arrestin signaling. Mol Biol Cell 2007; 18: 1979–1991.

  43. 43

    Valjent E, Pages C, Herve D, Girault JA, Caboche J . Addictive and non-addictive drugs induce distinct and specific patterns of ERK activation in mouse brain. Eur J Neurosci 2004; 19: 1826–1836.

  44. 44

    Berkeley JL, Levey AI . Cell-specific extracellular signal-regulated kinase activation by multiple G protein-coupled receptor families in hippocampus. Mol Pharmacol 2003; 63: 128–135.

  45. 45

    Cryan JF, Mombereau C, Vassout A . The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005; 29: 571–625.

  46. 46

    Dulawa SC, Hen R . Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 2005; 29: 771–783.

  47. 47

    Bodnoff SR, Suranyi-Cadotte B, Aitken DH, Quirion R, Meaney MJ . The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology 1988; 95: 298–302.

  48. 48

    Ressler KJ, Mayberg HS . Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci 2007; 10: 1116–1124.

  49. 49

    Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005; 45: 651–660.

  50. 50

    Vialou V, Bagot RC, Cahill ME, Ferguson D, Robison AJ, Dietz DM et al. Prefrontal cortical circuit for depression- and anxiety-related behaviors mediated by cholecystokinin: role of DeltaFosB. J Neurosci 2014; 34: 3878–3887.

  51. 51

    Warden MR, Selimbeyoglu A, Mirzabekov JJ, Lo M, Thompson KR, Kim SY et al. A prefrontal cortex-brainstem neuronal projection that controls response to behavioural challenge. Nature 2012; 492: 428–432.

  52. 52

    Lucas G, Compan V, Charnay Y, Neve RL, Nestler EJ, Bockaert J et al. Frontocortical 5-HT4 receptors exert positive feedback on serotonergic activity: viral transfections, subacute and chronic treatments with 5-HT4 agonists. Biol Psychiatry 2005; 57: 918–925.

  53. 53

    Vidal R, Castro E, Pilar-Cuellar F, Pascual-Brazo J, Diaz A, Rojo ML et al. Serotonin 5-HT4 receptors: a new strategy for developing fast acting antidepressants? Curr Pharm Des 2014; 20: 3751–3762.

  54. 54

    Etievant A, Lambas-Senas L, Abrial E, Betry C, Haddjeri N, Lucas G . Connection re-established: neurotransmission between the medial prefrontal cortex and serotonergic neurons offers perspectives for fast antidepressant action. Neuropsychiatry 2011; 1: 165–177.

  55. 55

    Maillet M, Gastineau M, Bochet P, Asselin-Labat ML, Morel E, Laverriere JN et al. Functional studies of the 5'-untranslated region of human 5-HT4 receptor mRNA. Biochem J 2005; 387 (Pt 2): 463–471.

  56. 56

    Samuels BA, Mendez-David I, Faye C, David SA, Pierz KA, Gardier AM et al. Serotonin 1A and Serotonin 4 receptors: essential mediators of the neurogenic and behavioral actions of antidepressants. Neuroscientist 2016; 22: 26–45.

  57. 57

    Krebs EG, Eisenman RN, Kuenzel EA, Litchfield DW, Lozeman FJ, Luscher B et al. Casein kinase II as a potentially important enzyme concerned with signal transduction. Cold Spring Harb Symp Quant Biol 1988; 53 (Pt 1): 77–84.

  58. 58

    Lee CQ, Yun YD, Hoeffler JP, Habener JF . Cyclic-AMP-responsive transcriptional activation of CREB-327 involves interdependent phosphorylated subdomains. Embo J 1990; 9: 4455–4465.

  59. 59

    Huillard E, Ziercher L, Blond O, Wong M, Deloulme JC, Souchelnytskyi S et al. Disruption of CK2beta in embryonic neural stem cells compromises proliferation and oligodendrogenesis in the mouse telencephalon. Mol Cell Biol 2010; 30: 2737–2749.

  60. 60

    Claeysen S, Faye P, Sebben M, Taviaux S, Bockaert J, Dumuis A . 5-HT4 receptors: cloning and expression of new splice variants. Ann NY Acad Sci 1998; 861: 49–56.

  61. 61

    de Groot RE, Rappel SB, Lorenowicz MJ, Korswagen HC . Protein kinase CK2 is required for Wntless internalization and Wnt secretion. Cell Signal 2014; 26: 2601–2605.

  62. 62

    Harraz MM, Tyagi R, Cortes P, Snyder SH . Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation. Mol Psychiatry 2016; 21: 313–319.

  63. 63

    Duman RS, Li N, Liu RJ, Duric V, Aghajanian G . Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012; 62: 35–41.

  64. 64

    Liu RJ, Fuchikami M, Dwyer JM, Lepack AE, Duman RS, Aghajanian GK . GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 2013; 38: 2268–2277.

  65. 65

    Crowley JJ, Blendy JA, Lucki I . Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test. Psychopharmacology 2005; 183: 257–264.

  66. 66

    Lucki I, Dalvi A, Mayorga AJ . Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 2001; 155: 315–322.

  67. 67

    Quesseveur G, David DJ, Gaillard MC, Pla P, Wu MV, Nguyen HT et al. BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities. Transl Psychiatry 2013; 3: e253.

  68. 68

    Martins LR, Lucio P, Melao A, Antunes I, Cardoso BA, Stansfield R et al. Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia. Leukemia 2014; 28: 179–182.

  69. 69

    Chon HJ, Bae KJ, Lee Y, Kim J . The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol 2015; 6: 70.

Download references

Acknowledgements

We thank Drs S Claeyssen and J Bockaert (INSERM-Montpellier) for the HA-HTR4 plasmid and Drs K Salas-Ramirez and A Kottmann (CCNY) for use of equipment. This work was supported by PSC-CUNY44, 45, 46 and 47 to HR and PSC-CUNY45 to BLF.

Author information

Correspondence to H Rebholz.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Molecular Psychiatry website

Supplementary information

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Castello, J., LeFrancois, B., Flajolet, M. et al. CK2 regulates 5-HT4 receptor signaling and modulates depressive-like behavior. Mol Psychiatry 23, 872–882 (2018). https://doi.org/10.1038/mp.2017.240

Download citation

Further reading